Abstract
The benefits of long-term cyclosporin (CyA) therapy are not yet established and must be weighed against its toxicity. We studied cardiovascular risk factors in 25 patients who received a kidney transplant between 1985 and 1989 and in whom CyA was discontinued. The protocol for discontinuing CyA involved starting azathioprine (Aza) and then weaning CyA over 6 weeks without changing the prednisone dose. Parameters collected from the patients' charts 3 months before (pre) and 3 months after conversion (post) and at the most current follow-up (cur) included serum creatinine, cholesterol, blood pressure, and anti-hypertensive medication. The severity of the hypertension was graded, based on a hypertension index reflecting the nature and dose of the anti-hypertensive medication. Of the 25 patients in whom CyA was discontinued, 2 experienced a rejection episode during conversion and were switched back to CyA; 1 patient had a rejection episode after conversion but remained on Aza. Converted patients demonstrated improved renal function (1/Cr pre 0.69±0.20, post 0.84±0.23, P<0.05), lower serum cholesterol levels (pre 6.8±1.0, post 5.8±1.2, P<0.05), lower mean arterial pressure (pre 111±14, post 102±8, P<0.05) and a lower hypertension index (pre 2.45±2.77, curr 1.62±1.70, P<0.05). Although conversion may carry some risk of acute rejection, it improves graft function and the cardiovascular risk profile significantly.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM, Young JB (1989) Effect of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53–56
Bennett W, Porter G (1980) Cyclosporine associated hypertension. Am J Med 85: 131–139
Brunchman TE, Brookshire CA (1991) Smooth muscle cell proliferation by conditioned media from cyclosporine-treated endothelial cells: a role of endothelin. Transplant Proc 2: 967–969
Chan MK, Varghese Z, Moorhead J (1981) Lipid abnormalities in uremia dialysis and transplantation. Kidney Int 19: 625–637
Chan MK, Varghese Z, Persuad JW (1981) The role of multiple pharmacotherapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol 15: 309–316
Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, Cooper KD, Boodsguard O, Duell EA, Annesly TM, Turcotte JG, Voorhees JJ (1986) Cyclosporine improves psoriasis in double-blind study. JAMA 256: 3110–3116
Harris KPG, Russell GI, Parvin SD, Veitch PS, Walls J (1986) Alteration in lipid and carbohydrate metabolism attributable to cyclosporine A in renal transplant patients. BMJ 292: 16
Higgins RM, Ratcliffe PJ (1991) Hypercholesterolaemia and vascular disease after transplantation. Transplant Rev 5: 131–149
Ibels LS, Stewart JH, Mahony JF, Sheil AGR (1974) Deaths from occlusive arterial disease in renal allograft recipients. BMJ 3: 522–554
Jackson JM, Lee HA (1982) The role of propranolol therapy and proteinuria in the etiology of post renal transplantation hyperlipidaemia. Clin Nephrol 18: 95–100
Kasiske B (1988) Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 84: 985–992
Kasiske BL, Umen AJ (1987) Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 66: 309–316
Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Venkateswara R (1991) The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 17: 700–707
Lindner AL, Charra B, Sherrard DJ, Scribner FJ (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697–701
Lipids Research Clinics Program (1984) Lipid research clinics coronary primary prevention trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–376
Mennander A, Tiisala S, Paavonen T, Halttunen J, Häyry P (1991) Chronic rejection of rat aortic allograft. II. Administration of cyclosporin induces accelerated allograft arteriosclerosis. Transpl Int 4: 173–179
Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248: 1465–1477
Pirsch JD, Arnbrust MJ, Knechtle SJ, Reed A, D'Alessandro AM, Sollinger HW, Belzer FO (1991) Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 23: 1363–1364
Raine AEG, Carter R, Mann JI, Morris PJ (1988) Adverse effect of cyclosporine on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 3: 458–463
Sagalowsky AI, Reisman ME, Dawidson I Toto R, Peters PC, Helderman JH (1988) Late cyclosporine conversion carries risk of irreversible rejection. Transplant Proc 20: 157–160
Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, Dunn DL, Sutherland DER, Najarian JS (1991) Causes of renal allograft loss: progress in the '80s, challenges for the '90s. 10th Annual American Society of Transplant Physicians Meeting, Chicago, p 65
Zoja C, Fusci L, Ghilardi F, Zilig P, Benigni A, Remuzzi A (1986) Cyclosporin-induced endothelial cell injury. Lab Invest 55: 455–462
Author information
Authors and Affiliations
About this article
Cite this article
Sutherland, F., Burgess, E., Klassen, J. et al. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transpl Int 6, 129–132 (1993). https://doi.org/10.1007/BF00336354
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00336354